# Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

> **NCT02875132** · PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 9 (actual)

## Conditions studied

- Acral Lentiginous Melanoma

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT02875132
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-15
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02875132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02875132, "Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT02875132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*